Inhibiting the Tyro3 pathway, which is linked to resistance against anti-PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) therapies, further resensitizes tumor cells to immunotherapy by promoting ferroptosis[139]. Here, PDCD1 is linked to neoplasm.